NEW YORK, March 5 - Orchid BioSciences and First Genetic Trust on Tuesday said they plan to co-develop and market a range of pharmacogenetic services to the private sector, academia, and health-care providers.

The alliance hopes to provide researchers the tools to asses the correlates between genotypes and phenotypes. Specifically, it seeks to generate patient registries and support clinical trials, develop and validate assays, and provide genotyping services, bioinformatics, and data management.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.